Click here - to use the wp menu builder

Pandion Therapeutics Appoints Rahul Kakkar, MD, as Chief Executive Officer

July 17, 2019

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Pandion Therapeutics appoints Rahul Kakkar, MD, as Chief Executive Officer. http://www.businesswire.com/news/home/20190717005190/en/Pandion-Therapeutics-Appoints-Rahul-Kakkar-MD-Chief/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

Pandion Therapeutics Appoints Rahul Kakkar, MD, as Chief Executive Officer

Recent Articles

Exicure Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Cavrotolimod

AavantiBio Adds Veteran Life Sciences Executive Douglas J. Swirsky as Chief Financial Officer and Treasurer

Xentria Announces Submission of an Investigational New Drug (IND) Application for XTMAB-16 in the Treatment of Sarcoidosis

Quantum Materials Corp Expands Executive Leadership Team To Execute Growth Strategy

Repertoire Immune Medicines Pre-publishes New Research Identifying Potential Mechanisms for Immune Escape of SARS-CoV-2 Variants to Support Novel Approaches for T Cell Based Therapeutic...